ArticleBMC infectious diseases2025
Seroprevalence of COVID-19 neutralizing antibodies among multi-ethnic staff of an Asian primary healthcare institution: insights from point-of-care testing and implications for booster vaccination decisions.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundCOVID-19 vaccines have been crucial for establishing immunity; however, emerging data suggest vaccine efficacy is reduced within six months. Healthcare staff face an elevated COVID-19 risk and should make an informed decision to receive timely boosters to maintain their immunity. This study aims to determine the COVID-19 neutralizing antibody (nAb) seroprevalence among primary care staff and the impact of serological testing on their vaccination decision.
methodsThis cross-sectional study involved multidisciplinary primary healthcare professionals working in 10 public primary care clinics from December 2022 to July 2023. A questionnaire captured sociodemographic data, COVID-19 related history and attitudes toward serological testing. Their COVID-19 nAb levels were measured via point-of-care CoVIm™ Rapid SARS-CoV-2 nAb Test and laboratory cPass™ SARS-CoV-2 nAb Detection Kit.
resultsThe study included 474 subjects, mostly female (88.8%), with a mean age of 40.6 years (SD = 12.3). All received at least two COVID-19 vaccinations, and 80.6% reported at least one infection. COVID-19 nAb seroprevalence was high (99.2%). Post-vaccination, 79.7% contracted COVID-19, with the median time to infection being 163 days. Most staff (93.9%) desired to know their COVID-19 immunity status through a finger pick test (77.0%) instead of venepuncture. Over two-thirds (68.1%) indicated the results would influence their booster vaccination decision.
conclusionThe study revealed a high seroprevalence of COVID-19 nAb among the fully vaccinated participating staff. The necessity for timely boosters is underscored by 79.7% contracting COVID-19 post-vaccination. Most subjects were willing to undergo point-of-care testing, with results potentially influencing their decisions for booster vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.